François Laliberté/LinkedIn
Aug 6, 2025, 12:52
RPTH Journal: Rivaroxaban vs Warfarin in PE with RV Dysfunction
RPTH Journal shared a new study on LinkedIn:
”Do clinical outcomes differ between patients treated with rivaroxaban vs warfarin for PE/RVD?
Rivaroxaban was more effective than warfarin without a significant increase in safety.”
Read the full article here.
Article: Effectiveness and safety of rivaroxaban vs warfarin in patients with pulmonary embolism and right ventricular dysfunction: a retrospective cohort study
Authors: François Laliberté, Behnood Bikdeli, Veronica Ashton, Guillaume Germain, Julien Boudreau, Manasvi Sundar, Sean D. MacKnight, Brahim Bookhart, Dereck Wentworth, Shawn Murphy, Yichuan G. Hsieh, Gregory Piazza
Find the latest scientific advances featured in Hemostasis Today.
Behnood Bikdeli
Brahim Bookhart
Dereck Wentworth
François Laliberté
Gregory Piazza
Guillaume Germain
Health
Hematology
Hemostasis Today
Julien Boudreau
Manasvi Sundar
Medicine
PE
Pulmonary embolism
right ventricular dysfunction
Rivaroxaban
Rivaroxaban vs Warfarin
RPTH Journal
RVD
Sean D. MacKnight
Shawn Murphy
Veronica Ashton
Warfarin
Yichuan G. Hsieh
-
Aug 12, 2026, 07:49Alan Dursun: Phnom Penh, Cambodia – Part 3 – Turning Partnership into Action
-
Aug 12, 2026, 06:55Alejandro González Veliz: A Good PCI is not Just about Opening the Artery
-
Aug 12, 2026, 06:39Abdulmalik Alnuqydan: Why Do We Transfuse RBCs Less Than 7 Days Old to Newborns?
-
Aug 12, 2026, 06:24Lucas Jae: How Mitochondria Sense Heme Scarcity to Regulate Heme and Globin Production
-
Aug 12, 2026, 06:09Luis Tam։ New CDC Global Health Security Funding Opportunities
-
Aug 12, 2026, 06:09Yan Leyfman: Curative Strategies and Precision Medicine in Sickle Cell Disease
-
Aug 12, 2026, 06:01Sophie He: Exploring Manufacturing Scalability and Cell Separation
-
Aug 12, 2026, 05:54Yuan Goessi: One Bleed Is One Too Many for a Lifetime of Haemophilia A
-
Aug 12, 2026, 05:47Shehab Mohamed: Philadelphia Negative MPNs in AYA vs Older Adults in Qatar